Advancing Antimicrobial Science: Targeting Biofilms and Drug-Resistant Pathogens

Breakthrough solutions tackling biofilms, antibiotic resistance, and chronic infections

At MHCombiotic, we are pioneering Combiotic™ technology, a cutting-edge antimicrobial platform designed to overcome the growing global crisis of antimicrobial resistance (AMR).

Through extensive research and collaborations with leading institutions, we have developed targeted solutions to combat wound and respiratory infections.

Mechanism of Action

Our comprehensive multi-OMICS studies, combined with probe-based assays, have shown that our plant-based agents target the bacterial cell membrane in the initial step. The bacterial cell membrane has a composition that is markedly different from eukaryotic cell membranes, explaining the agents’ selectivity and thus their safety as antibacterial agents. Moreover, these agents increase glutathione (GSH) levels in eukaryotic cells.

Advancing Antimicrobial Solutions for Critical Infections

Innovative Pipeline

Medical Devices

Discovery

Validation

Biocompatibility

Approval

Commercialization

ComBatic™ Antimicrobial Wound Care

Therapeutics

Discovery

Pre-Clinical

Phase I

Phase II

Phase III

COMB-NEBTM for Respiratory Infection

Therapeutics

Discovery

Pre-Clinical

Phase I

Phase II

Phase III

MHC-200 for Systemic infection

Wound Care – Medical Device

Advanced Barrier Technology for Clean, Hydrated Wound Healing

  • The ComBatic™ wound care line combines a hydrated barrier hydrogel and irrigation solution designed to support the body’s natural healing process. Both formulations help cleanse the wound surface, maintain optimal moisture, and create a protective barrier against external contaminants.
  • Formulated with biocompatible and antioxidant-supportive ingredients, ComBatic™ products help maintain a balanced wound environment and minimize microbial growth within the dressing, promoting safe, effective, and comfortable recovery.
  • Developed through extensive R&D and screening of 18,000+ combinations, ComBatic™ technology demonstrates strong laboratory performance in wound cleansing, protection, and recovery support.
Explore ComBatic Wound Care

Respiratory – Therapeutics

Antimicrobial and Anti-Inflammatory Approach for Respiratory Infections

  • Antibacterial and antibiofilm properties targeting resistant pathogens
  • Anti-inflammatory and antioxidant effects to support lung health
  • Addresses high-risk patient populations prone to severe complications

Respiratory infections remain a leading cause of global mortality, disproportionately affecting infants, the elderly, and immunocompromised individuals. Combiotic™ technology is being investigated for its broad-spectrum antimicrobial properties, capable of inhibiting biofilm formation, bacterial proliferation, and inflammation. Its ability to mitigate oxidative stress and enhance antimicrobial potency offers potential therapeutic applications in managing drug-resistant respiratory infections.

Systemic Infection – Therapeutics

Integrated Solutions for Sepsis: Fighting Pathogens and Overcoming Inflammation

  • Targets aggressive pathogens and their biofilms contributing to sepsis
  • Modulates overwhelming inflammation and oxidative stress
  • Aims to protect vital organs and improve patient outcomes

Sepsis is a life-threatening condition that arises when the body’s response to an infection causes injury to its own tissues and organs. It is a leading cause of mortality globally, particularly among the elderly, immunocompromised, and those with chronic diseases. Combiotic™ technology is being investigated for its potential to address the complex challenges of sepsis by offering broad-spectrum antimicrobial properties to combat the underlying infection, while also mitigating the severe inflammatory and oxidative stress responses that lead to organ dysfunction. Its ability to inhibit bacterial proliferation and biofilm formation, alongside its anti-inflammatory and antioxidant effects, offers a novel therapeutic strategy to improve outcomes in this critical condition.

Let’s Connect and Innovate Together

Have questions about our technology, research, or partnerships? We’d love to hear from you!

Contact us